Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 17/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 14/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5903342 | 0.88 | CASP1 (0.48) | CASP1CASP8CASP3 | |
| SCHEMBL5903377 | 0.85 | CASP1 (0.47) | CASP1CASP8CASP3F2F10 | |
| SCHEMBL5903111 | 0.85 | CASP1 (0.63) | CASP1CASP8CASP3 | |
| SCHEMBL5903065 | 0.84 | CASP1 (0.46) | CASP1CASP8CASP3F2F10 | |
| SCHEMBL5903302 | 0.83 | CASP1 (0.39) | CASP1CASP8CASP3F2F10 | |
| SCHEMBL5903269 | 0.80 | CASP1 (0.76) | CASP1CASP8CASP3 | |
| SCHEMBL5903011 | 0.80 | CASP1 (0.36) | CASP1CASP8CASP3F2F10 | |
| SCHEMBL5902881 | 0.79 | CASP1 (0.36) | CASP1CASP8CASP3F2F10 | |
| SCHEMBL5903228 | 0.79 | CASP1 (0.43) | CASP1CASP8CASP3 | |
| SCHEMBL5903308 | 0.78 | CASP1 (0.43) | CASP1CASP8CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001899-B2 | Interleukin converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1511491-A1 | DERIVATIVES OF AZEPINE AND THIAZEPAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040009966-A1 | 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis | THE PROCTER & GAMBLE COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003103677-A1 | DERIVATIVES OF AZEPINE AND THIAZERAN AS INTERLEUKIN CONVERTING ENZYME INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009966-A1 | 7-member ring N-heterocycles that have a cysteine trap substitution; treating osteoarthritis | TST, SYVN1, TXN2 | CASP1 1759/4885CASP8 1889/4885CASP3 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.